** Shares of AI biologics firm Absci Corp ABSI.O rise 3.7% to $3.34 premarket
** Brokerage Needham initiates coverage with a "buy" rating, sets price target of $9
** Brokerage says Absci stands out from the pack due to its practical approach to drug development
** Says unlike many of its peers, Absci generates proprietary, well-annotated, wet-lab data at scale, adds, "It is our view that the real currency for companies focused on drug development in the AI age is the quality of the data used"
** Says co has potential best-in-class assets in high-value therapeutic spaces such as inflammatory bowel disease
** 8 of 8 brokerages rate the stock "buy" or higher; their median PT is $9
** ABSI had fallen 37.6% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。